- Home
- AVIR vs XFOR Comparison
AVIR vs XFOR Comparison
Compare AVIR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | XFOR |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.5M | 377.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVIR | XFOR |
|---|---|---|
| Price | $4.89 | $3.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $9.00 |
| AVG Volume (30 Days) | 330.7K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $1.35 |
| 52 Week High | $6.45 | $4.83 |
Technical Indicators
Market Signals| Indicator | AVIR | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 46.52 |
| Support Level | $4.14 | $3.50 |
| Resistance Level | $6.37 | $4.38 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 82.72 | 9.52 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.